The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Phase II Trial of Lapatinib for Brain Metastases in Patients With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Open accessAbstract
Purpose: One third of women with advanced human epidermal growth factor receptor 2 (HER-2)–positive breast cancer develop brain metastases; a subset progress in the CNS despite standard approaches. Medical therapies for refractory brain metastases are neither well-studied nor established. We evaluated the safety and efficacy of lapatinib, an oral inhibitor of epidermal growth factor receptor (EGFR) and HER-2, in patients with HER-2–positive brain metastases. Patients and Methods: Patients had HER-2–positive breast cancer, progressive brain metastases, prior trastuzumab treatment, and at least one measurable metastatic brain lesion. Patients received lapatinib 750 mg orally twice a day. Tumor response was assessed by magnetic resonance imaging every 8 weeks. The primary end point was objective response (complete response [CR] plus partial response [PR]) in the CNS by Response Evaluation Criteria in Solid Tumors (RECIST). Secondary end points included objective response in non-CNS sites, time to progression, overall survival, and toxicity. Results: Thirty-nine patients were enrolled. All patients had developed brain metastases while receiving trastuzumab; 37 had progressed after prior radiation. One patient achieved a PR in the brain by RECIST (objective response rate 2.6%, 95% conditional CI, 0.21% to 26%). Seven patients (18%) were progression free in both CNS and non-CNS sites at 16 weeks. Exploratory analyses identified additional patients with some degree of volumetric reduction in brain tumor burden. The most common adverse events (AEs) were diarrhea (grade 3, 21%) and fatigue (grade 3, 15%). Conclusion: The study did not meet the predefined criteria for antitumor activity in highly refractory patients with HER-2–positive brain metastases. Because of the volumetric changes observed in our exploratory analysis, further studies are underway utilizing volumetric changes as a primary end point.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer
Romond, E. H., Perez, E. A., Bryant, J., Suman, V. J., Geyer, C. E., Davidson, N. E., Tan-Chiu, E., Martino, S., Paik, S., Kaufman, P. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052122 · Cited by 5,356
Trastuzumab-Induced Hepatotoxicity: A Case Report
Vucicevic, D., Carey, E. J., & Karlin, N. J. (2013) · Breast Care · doi:10.1159/000346844 · Cited by 4,415
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Geyer, C. E., Forster, J., Lindquist, D., Chan, S., Romieu, C. G., Pienkowski, T., Jagiello-Gruszfeld, A., Crown, J., Chan, A., Kaufman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa064320 · Cited by 3,425
Vogel, C. L., Cobleigh, M. A., Tripathy, D., Gutheil, J. C., Harris, L. N., Fehrenbacher, L., Slamon, D. J., Murphy, M., Novotny, W. F., Burchmore, M., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.3.719 · Cited by 1,860
Bendell, J. C., Domchek, S. M., Burstein, H. J., Harris, L., Younger, J., Kuter, I., Bunnell, C., Rue, M., Gelman, R., & Winer, E. (2003) · Cancer · doi:10.1002/cncr.11436 · Cited by 1,320
Self-citationLamon, D. E. J. S., Eyland, B. R. L., Hak, S. T. S., Uchs, H. A. F., Aton, V. I. P., Ajamonde, A. L. B., LeMing, T., Iermann, W. O. E., Olter, J. A. W., Egram, M. A. P., et al. (2009) · Cited by 1,199
CNS Metastases in Breast Cancer
Lin, N. U., Bellon, J. R., & Winer, E. P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.175 · Cited by 715
Self-citationXia, W., Mullin, R. J., Keith, B. R., Liu, L.-H., Ma, H., Rusnak, D. W., Owens, G., Alligood, K. J., & Spector, N. L. (2002) · Oncogene · doi:10.1038/sj.onc.1205794 · Cited by 664
Cited by
CNS Metastases in Breast Cancer: Old Challenge, New Frontiers
Lin, N. U., Amiri-Kordestani, L., Palmieri, D., Liewehr, D. J., & Steeg, P. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0790 · Cited by 1,286
Self-citationRoss, J. S., Slodkowska, E. A., Symmans, W. F., Pusztai, L., Ravdin, P. M., & Hortobagyi, G. N. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0230 · Cited by 1,144
Achrol, A. S., Rennert, R. C., Anders, C., Soffietti, R., Ahluwalia, M. S., Nayak, L., Peters, S., Arvold, N. D., Harsh, G. R., Steeg, P. S., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0055-y · Cited by 1,034
Johnston, S., Pippen, J., Pivot, X., Lichinitser, M., Sadeghi, S., Dieras, V., Gomez, H. L., Romieu, G., Manikhas, A., Kennedy, M. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.3734 · Cited by 1,025
Bachelot, T., Romieu, G., Campone, M., Diéras, V., Cropet, C., Dalenc, F., Jimenez, M., Le Rhun, E., Pierga, J.-Y., Gonçalves, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70432-1 · Cited by 737
Lin, N. U., Claus, E., Sohl, J., Razzak, A. R., Arnaout, A., & Winer, E. P. (2008) · Cancer · doi:10.1002/cncr.23930 · Cited by 727
Self-citationLin, N. U., Diéras, V., Paul, D., Lossignol, D., Christodoulou, C., Stemmler, H.-J., Roché, H., Liu, M. C., Greil, R., Ciruelos, E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1080 · Cited by 658
Self-citationLe Rhun, E., Weller, M., Brandsma, D., Van den Bent, M., de Azambuja, E., Henriksson, R., Boulanger, T., Peters, S., Watts, C., Wick, W., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx221 · Cited by 637
The biology of brain metastases—translation to new therapies
Eichler, A. F., Chung, E., Kodack, D. P., Loeffler, J. S., Fukumura, D., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.58 · Cited by 567
Current approaches to the management of brain metastases
Suh, J. H., Kotecha, R., Chao, S. T., Ahluwalia, M. S., Sahgal, A., & Chang, E. L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0320-3 · Cited by 553
Soffietti, R., Abacioglu, U., Baumert, B., Combs, S. E., Kinhult, S., Kros, J. M., Marosi, C., Metellus, P., Radbruch, A., Villa Freixa, S. S., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/now241 · Cited by 496
Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases
MEDINA, P., & GOODIN, S. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.08.008 · Cited by 377
Piccart-Gebhart, M., Holmes, E., Baselga, J., de Azambuja, E., Dueck, A. C., Viale, G., Zujewski, J. A., Goldhirsch, A., Armour, A., Pritchard, K. I., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1797 · Cited by 371
The Evolving Landscape of Brain Metastasis
Valiente, M., Ahluwalia, M. S., Boire, A., Brastianos, P. K., Goldberg, S. B., Lee, E. Q., Le Rhun, E., Preusser, M., Winkler, F., & Soffietti, R. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.01.003 · Cited by 309
Current approaches to the treatment of metastatic brain tumours
Owonikoko, T. K., Arbiser, J., Zelnak, A., Shu, H.-K. G., Shim, H., Robin, A. M., Kalkanis, S. N., Whitsett, T. G., Salhia, B., Tran, N. L., et al. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.25 · Cited by 304
Raub, T. J., Wishart, G. N., Kulanthaivel, P., Staton, B. A., Ajamie, R. T., Sawada, G. A., Gelbert, L. M., Shannon, H. E., Sanchez-Martinez, C., & De Dios, A. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.062745 · Cited by 284
“A central role of this pathway has also been established in other tumors with a high incidence of brain metastases, such as breast cancer, including HER2-positive breast cancer (Landis et al., 2006; Malumbres and Barbacid, 2006; Yu et al., 2006; Lin et al., 2008), lung cancer (Eichler and Loeffler, 2007), and melanoma…”
BackgroundEffect of Lapatinib on the Outgrowth of Metastatic Breast Cancer Cells to the Brain
Gril, B., Palmieri, D., Bronder, J. L., Herring, J. M., Vega-Valle, E., Feigenbaum, L., Liewehr, D. J., Steinberg, S. M., Merino, M. J., Rubin, S. D., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn216 · Cited by 283
Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease
(2010) · National Academies Press eBooks · doi:10.17226/12869 · Cited by 276
Third consensus on medical treatment of metastatic breast cancer
Beslija, S., Bonneterre, J., Burstein, H. J., Cocquyt, V., Gnant, M., Heinemann, V., Jassem, J., Köstler, W. J., Krainer, M., Menard, S., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp261 · Cited by 263
Self-citationPolli, J. W., Olson, K. L., Chism, J. P., John-Williams, L. S., Yeager, R. L., Woodard, S. M., Otto, V., Castellino, S., & Demby, V. E. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.108.024646 · Cited by 256
Kodack, D. P., Chung, E., Yamashita, H., Incio, J., Duyverman, A. M. M. J., Song, Y., Farrar, C. T., Huang, Y., Ager, E., Kamoun, W., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216078109 · Cited by 153
The role of systemic and targeted therapies in brain metastases
Franceschi, E., Bartolotti, M., Poggi, R., Battista, M. D., Palleschi, D., & Brandes, A. A. (2014) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2014.856760 · Cited by 7
Metadata
- Authors
- Lin, N. U., Carey, L. A., Liu, M. C., Younger, J., Come, S. E., Ewend, M., Harris, G. J., Bullitt, E., Van den Abbeele, A. D., Henson, J. W., Li, X., Gelman, R., Burstein, H. J., Kasparian, E., Kirsch, D. G., Crawford, A., Hochberg, F., & Winer, E. P.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-04-20
- Volume
- 26
- Issue
- 12
- Pages
- 1993-1999
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2119997685
- Cited by
- 456
- References
- 26
- FWCI
- 40.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.